




# PHARMACEUTICAL 2021

Global Blood Therapeutics Inc.  
Rank 214 of 402





RealRate

# PHARMACEUTICAL 2021

Global Blood Therapeutics Inc.  
Rank 214 of 402



The relative strengths and weaknesses of Global Blood Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Global Blood Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Global Blood Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is 91%, being 43% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	632,163
Cost of Goods Sold	1,986
Intangible Assets	0
Liabilities, Current	79,032
Liabilities, Non-Current	228,813
Other Assets	53,957
Other Compr. Net Income	-452
Other Expenses	-984
Other Liabilities	0
Other Net Income	-4,381
Other Revenues	123,803
Property and Equipment	37,882
Research and Development	155,122
Selling, General and Administrative Expense	210,851

Output Variable	Value in 1000 USD
Assets	724,002
Liabilities	307,845
Expenses	366,975
Revenues	123,803
Stockholders Equity	416,157
Net Income	-247,553
Comprehensive Net Income	-247,779
Economic Capital Ratio	91%